PV3B Stock Overview
A clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EyePoint Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.70 |
| 52 Week High | US$28.60 |
| 52 Week Low | US$5.25 |
| Beta | 1.72 |
| 1 Month Change | -44.14% |
| 3 Month Change | -57.22% |
| 1 Year Change | 71.12% |
| 3 Year Change | 44.53% |
| 5 Year Change | -25.63% |
| Change since IPO | -53.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| PV3B | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.4% | 4.7% | -0.3% |
| 1Y | 71.1% | -19.6% | 4.5% |
Return vs Industry: PV3B exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.
Return vs Market: PV3B exceeded the German Market which returned 4.5% over the past year.
Price Volatility
| PV3B volatility | |
|---|---|
| PV3B Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: PV3B's share price has been volatile over the past 3 months.
Volatility Over Time: PV3B's weekly volatility has decreased from 34% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 121 | Jay Duker | eyepointpharma.com |
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
EyePoint Pharmaceuticals, Inc. Fundamentals Summary
| PV3B fundamental statistics | |
|---|---|
| Market cap | €581.78m |
| Earnings (TTM) | -€72.61m |
| Revenue (TTM) | €46.02m |
12.6x
P/S Ratio-8.0x
P/E RatioIs PV3B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PV3B income statement (TTM) | |
|---|---|
| Revenue | US$50.02m |
| Cost of Revenue | US$85.63m |
| Gross Profit | -US$35.61m |
| Other Expenses | US$43.30m |
| Earnings | -US$78.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | -71.20% |
| Net Profit Margin | -157.77% |
| Debt/Equity Ratio | 0% |
How did PV3B perform over the long term?
See historical performance and comparison